Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles
- PMID: 15142340
- DOI: 10.1211/0022357023303
Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles
Abstract
Rats were intraperitoneally administered 40 mg x kg(-1) of paclitaxel or docetaxel dissolved in various drug solutions. The drug solutions were prepared using 20 mL of saline, adding 4.2% Cremophor EL (crEL) for paclitaxel (TXL), and 1.5% Polysorbate-80 (PS-80) (TXT), 7.5% PS-80 (TXT+PS-80) or 4.2% crEL (TXT+crEL) for docetaxel. The apparent first-order absorption rate constant from the peritoneal cavity (k(a)) of TXL was about one-twentieth of that of TXT. The ratio of the area under the concentration-time curve of drug in plasma over that in ascites for TXL was about one-third of that of TXT. The values of the above ratio and the k(a) of TXT+PS-80 and TXT+crEL were similar to those of TXL. After intraperitoneal administration, the values of the blood-to-plasma concentration ratio in the four groups were similar and independent of time. In the in-vitro study, PS-80 and crEL caused similar, concentration-dependent decreases of drug permeation into red blood cells after a 15-min incubation of rat blood with 10 microg x mL(-1) of TXL. We demonstrated that the disposition kinetics of taxanes after intraperitoneal administration to rats was strongly influenced, in a concentration-dependent manner, by the surfactant vehicle used, crEL or PS-80.
Similar articles
-
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.Cancer Lett. 2010 Jan 28;287(2):182-6. doi: 10.1016/j.canlet.2009.06.018. Epub 2009 Jul 15. Cancer Lett. 2010. PMID: 19608331
-
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613
-
Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.Cancer Chemother Pharmacol. 2002 Dec;50(6):445-53. doi: 10.1007/s00280-002-0531-6. Epub 2002 Oct 16. Cancer Chemother Pharmacol. 2002. PMID: 12451470
-
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.Clin Pharmacokinet. 2003;42(7):665-85. doi: 10.2165/00003088-200342070-00005. Clin Pharmacokinet. 2003. PMID: 12844327 Review.
-
Role of formulation vehicles in taxane pharmacology.Invest New Drugs. 2001 May;19(2):125-41. doi: 10.1023/a:1010618632738. Invest New Drugs. 2001. PMID: 11392447 Review.
Cited by
-
Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent.ScientificWorldJournal. 2013 Mar 25;2013:720858. doi: 10.1155/2013/720858. Print 2013. ScientificWorldJournal. 2013. PMID: 23589707 Free PMC article. Review.
-
Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model.Pleura Peritoneum. 2017 Jun 1;2(2):95-102. doi: 10.1515/pp-2017-0002. Epub 2017 Mar 30. Pleura Peritoneum. 2017. PMID: 30911637 Free PMC article.
-
Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.Pharm Res. 2007 Sep;24(9):1691-701. doi: 10.1007/s11095-007-9298-0. Epub 2007 Apr 20. Pharm Res. 2007. PMID: 17447121 Free PMC article.
-
Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery.Pharm Res. 2025 Aug 25. doi: 10.1007/s11095-025-03917-0. Online ahead of print. Pharm Res. 2025. PMID: 40855029
-
Disposition kinetics of taxanes in peritoneal dissemination.Gastroenterol Res Pract. 2012;2012:963403. doi: 10.1155/2012/963403. Epub 2012 May 16. Gastroenterol Res Pract. 2012. PMID: 22666236 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources